Induced Pluripotent Stem Cells
|
To facilitate research on differentiated cell types and other biomedical investigations, the NIGMS Repository offers human induced pluripotent stem cell (hiPSC) lines derived from apparently healthy individuals or from individuals affected with heritable diseases. These hiPSCs were created using a variety of reprogramming techniques*.
Some of the available hiPSC lines were derived from externally submitted iPSC lines, where a distribution stock was made. Others were derived from established LCLs or Fibroblast lines available in the catalog. In addition to QC tests (viability, contamination, karyotyping, microarray genotyping, and microsatellite matches with the parent cell culture), extensive pluripotency characterizations are performed on each NIGMS Repository hiPSC line. Pluripotency characterizations include the following assays:
- Surface antigen expression
- Embryoid body formation
- PluriTest gene expression assay
A complete Certificate of Analysis (CofA) that includes images and quantitative test results is available for each hiPSC line. The CofA PDF specifies which pluripotency characterizations were performed on each hiPSC line.
The Protocol PDFs outline the proper steps for successful handling of the hiPSCs. Additional information is also found on the CofA PDF, including necessary media components, substrates, passage methods, and split ratios.
* For commercial purposes, please note that Limited Use Label Licenses (LULLs) may apply.
|
|
Apparently Healthy hiPSC Lines
|
| Records Return:
(18)
|
|
|
|
|
|
Disease-Specific hiPSC Lines
|
| Records Return:
(90)
|
>
|
|
|
| Catalog ID | Diagnosis | Parent Line | Transformant | Gender | LULL | Age | Race | Biopsy Source | Affected Status | Gene(s) | Mutation(s) | Family and Associated Specimens | Certificate of Analysis | Protocol |
| GM28559 | ALAGILLE SYNDROME 1; ALGS1 | GM11091 | Reprogrammed (Sendai) | Female | Sendai-Cyto Tune | 17 YR | White | Skin | Yes | | | 1324 | CofA PDF | Protocol PDF |
| GM24666 | ALZHEIMER DISEASE; AD | SAD 2.2 | Reprogrammed (Retroviral) | Male | IP ACADEMIA JAPAN | 83 YR | White | Skin | Yes | | | 3234 | CofA PDF | Protocol PDF |
| GM24675 | ALZHEIMER DISEASE; AD | APP 2.3 | Reprogrammed (Retroviral) | Female | IP ACADEMIA JAPAN | 60 YR | Not Reported | Skin | Yes | | | 3236 | CofA PDF | Protocol PDF |
| GM28249 | CANAVAN DISEASE | GM00059 | Reprogrammed (Sendai) | Female | Sendai-Cyto Tune | 1 YR | Not Reported | Skin | Yes | ASPA ASPA ASPA | ALA305GLU
TYR231TER
GLY176ASP
| 424 | CofA PDF | Protocol PDF |
| GM28915 | CANCER OF THE BREAST, FAMILIAL; BCS | GM27953 | Reprogrammed (Sendai) | Female | Sendai-Cyto Tune | 55 YR | White | Blood | Yes | CHEK2 | c.190G>A (p.Glu64Lys)
| 3551 | CofA PDF | Protocol PDF |
| GM27857 | CEREBRAL CREATINE DEFICIENCY SYNDROME 1; CCDS1 | GM27448 | Reprogrammed (Sendai) | Male | Sendai-Cyto Tune | 4 YR | Asian | Skin | Yes | SLC6A8 | DEL EX10-11
| 3486 | CofA PDF | Protocol PDF |
| GM28937 | CEREBRAL CREATINE DEFICIENCY SYNDROME 1; CCDS1 | GM27863 | Reprogrammed (Sendai) | Male | Sendai-Cyto Tune | 4 YR | White | Blood | Yes | SLC6A8 | c.1222_1224DELTTC (p.F408del)
| 3466 | CofA PDF | Protocol PDF |
| GM28589 | CEREBRAL CREATINE DEFICIENCY SYNDROME 3; CCDS3 | GM27955 | Reprogrammed (Sendai) | Female | Sendai-Cyto Tune | 18 YR | Asian | Blood | Yes | GATM GATM | IVS3+1G>T (c.484+1G>T)
IVS3+1G>T (c.484+1G>T)
| | CofA PDF | Protocol PDF |
| GM27177 | CEROID LIPOFUSCINOSIS, NEURONAL 2, LATE INFANTILE TYPE; CLN2 | GM20385 | Reprogrammed (Episomal) | Female | IP ACADEMIA JAPAN | 11 YR | Not Reported | | Yes | CLN2 CLN2 | IVS5AS, G>C, -1
IVS5-1G>A
| 3406 | CofA PDF | Protocol PDF |
| GM27465 | CEROID LIPOFUSCINOSIS, NEURONAL 2, LATE INFANTILE TYPE; CLN2 | GM16485 | Reprogrammed (Sendai) | Female | Sendai-Cyto Tune | | Not Reported | Skin | Yes | CLN2 CLN2 | ARG208TER
ARG127TER
| 3451 | CofA PDF | Protocol PDF |
| GM28380 | CEROID LIPOFUSCINOSIS, NEURONAL 2, LATE INFANTILE TYPE; CLN2 | GM16486 | Reprogrammed (Sendai) | Male | Sendai-Cyto Tune | | | Skin | Yes | CLN2 CLN2 | IVS5AS, G>C, -1
ARG127GLN
| | CofA PDF | Protocol PDF |
| GM26650 | CHOROIDEREMIA; CHM | GM25393 | Reprogrammed (Sendai) | Male | Sendai-Cyto Tune | 57 YR | White | Skin | Yes | CHM CHM | c.189+1G>T
ALA117ALA
| 3214 | CofA PDF | Protocol PDF |
| GM26663 | CHOROIDEREMIA; CHM | GM25383 | Reprogrammed (Sendai) | Male | Sendai-Cyto Tune | 20 YR | White | Skin | Yes | CHM CHM CHM | ARG270TER
c.116+215insCCTTT
c.116+80C>T
| 3210 | CofA PDF | Protocol PDF |
| GM27381 | CONGENITAL DISORDER OF DEGLYCOSYLATION; CDDG | GM25344 | Reprogrammed (Sendai) | Male | Sendai-Cyto Tune | 10 YR | White | Skin | Yes | NGLY1 NGLY1 CACNA1S | GLN208TER
GLY310GLY
THR1354SER
| 3196 | CofA PDF | Protocol PDF |
| GM24683 | CYSTIC FIBROSIS; CF | GM01014 | Reprogrammed (Episomal) | Male | IP ACADEMIA JAPAN | 13 YR | White | Skin | Yes | CFTR CFTR | PHE508DEL
PHE508DEL
| 93 | CofA PDF | Protocol PDF |
| GM23226 | DIABETES MELLITUS, JUVENILE-ONSET INSULIN-DEPENDENT; IDDM | GM02416 | Reprogrammed (Retroviral) | Female | IP ACADEMIA JAPAN | 42 YR | American Indian/Alaska Native | Skin | Yes | | | 383 | CofA PDF | Protocol PDF |
| GM24559 | DYSTROPHIA MYOTONICA 1; DM1 | GM04602 | Reprogrammed (Episomal) | Female | IP ACADEMIA JAPAN | 2 YR | White | Skin | Yes | DMPK | (CTG)n EXPANSION
| 583 | CofA PDF | Protocol PDF |
| GM26017 | EPIDERMOLYSIS BULLOSA: DYSTROPHIC, JUNCTIONAL, OR SIMPLEX TYPES | GM10269 | Reprogrammed (Sendai) | Male | Sendai-Cyto Tune | 4 YR | White | | Yes | | | 1186 | CofA PDF | Protocol PDF |
| GM27327 | FACIOSCAPULOHUMERAL MUSCULAR DYSTROPHY 1; FSHD1 | GM16277 | Reprogrammed (Episomal) | Female | IP ACADEMIA JAPAN | 77 YR | Not Reported | Peripheral vein | Yes | | | 1939 | CofA PDF | Protocol PDF |
| GM28385 | FIBRODYSPLASIA OSSIFICANS PROGRESSIVA; FOP | GM00513 | Reprogrammed (Sendai) | Female | Sendai-Cyto Tune | 16 YR | White | Skin | Yes | | | | CofA PDF | Protocol PDF |
|
|